SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Trade/Invest with Options Jerry a Point & Figure Chartist -- Ignore unavailable to you. Want to Upgrade?

To: GREENLAW4-7 who wrote (3846)10/1/2001 8:31:15 AM
From: Jerry Olson  Read Replies (1) | Respond to of 5893
 
OK, but taking profits on recent trades is prudent as well...

no sense in selling dogs with fleas at this point...not if you rode them all the way down to here???

unless you wish to raise some cash to buy OTHER stocks...



To: GREENLAW4-7 who wrote (3846)10/1/2001 8:36:32 AM
From: Jerry Olson  Read Replies (1) | Respond to of 5893
 
Live Headline
01-Oct-01
08:35 ET Millennium Pharm (MLNM) 17.76: First Union Securities out with positive comments following Friday's Phase II trial results on Campath reported by Millennium's marketing partner, Schering AG; the firm has a Strong Buy rating on MLNM with a $42 price target.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News